

## Claims

1. A method for the treatment and/or prophylaxis of Type II diabetes, which method comprises the administration, to a human or non-human mammal, of an effective non-toxic pharmaceutically acceptable amount of an NO synthase inhibitor or a pharmaceutically acceptable derivative thereof.
2. A method according to claim 1, for the prophylactic treatment of Type II diabetes.
3. A method according to claim 1 or claim 2, for delaying or preventing the progression from hyperinsulinaemia to hyperglycaemia.
4. A method according to any one of claims 1 to 3, wherein the NO synthase inhibitor is selected from aminoguanidine, n-monomethylarginine, or other analogues of l-arginine.
5. A method according to any one of claims 1 to 4, wherein the NO synthase inhibitor is aminoguanidine.
6. An NO synthase inhibitor, or a pharmaceutically acceptable derivative thereof, for use in the treatment of and/or prophylaxis of Type II diabetes.
7. An NO synthase inhibitor, or a pharmaceutically acceptable derivative thereof, for use in the manufacture of a medicament for the treatment and/or prophylaxis of Type II diabetes.
8. A pharmaceutical composition for the treatment and/or prophylaxis of Type II diabetes, which composition comprises an NO synthase inhibitor, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier therefor.